Cortexyme Stock Plunges On FDA Hold On Atuzaginstat’s IND

The FDA has placed a clinical hold on Cortexyme Inc’s CRTX atuzaginstat (COR388) Investigational New Drug application (IND 134303). 

[IMPORTANT]  If you are wondering what is happening in the markets and where you need to put your moneyright  now, do not waste anymore time! Benzinga Trading School students are taking advantage of the current market landscape to not only protect their wealth but build it using hedge-fund tested strategies. Click Here Now to Get Free Access (and no, a credit card is not required)

  • The Company plans to provide additional updates pending continued engagement with FDA.
  • Cortexyme is immediately implementing a cost reduction program to rationalize operations, providing an expected cash runway through 2024. 
  • Related content: Benzinga’s Full FDA Calendar.
  • The Company intends to prioritize the development of its next-generation gingipain inhibitor, COR588, in Alzheimer’s disease. 
  • COR588 is currently completing a Phase 1 SAD/MAD study, and results are expected in Q2 of 2022. 
  • In addition, Cortexyme plans to explore strategic alternatives for its coronavirus program and non-Alzheimer’s indications for COR388. 
  • In November last year, the Company presented data from Phase 2/3 GAIN Trial of atuzaginstat in Alzheimer’s Disease.
  • The 643-participant 48-week trial failed to meet statistical significance on its co-primary cognitive and functional endpoints in the overall cohort.
  • Price Action: CRTX shares are down 34.0% at $5.98 during the premarket session on the last check Wednesday.

If you are not using this trading strategy, you are leaving money on the table…

If you are blindly looking up and trading stocks the way 99% of traders are, you are missing on HUGE potential returns. Even new traders who started following this option trading strategy instantly began seeing returns they wouldn’t have had otherwise. With even two trades per month with this strategy, you will start seeing the difference in your trading account. Don’t waste any more time “guessing” and “getting lucky”. Click Here to See if you Qualify for Benzinga Options!

For today only, we are gifting away our Benzinga Options Starter newsletter for only $7. This includes two heavily researched trades per month from lead trader, Nic Chahine. For the same cost of a cup of coffee, less than the cost of a Netflix subscription and less than the average order at McDonalds you will receive top tier education and winning trade alerts to maximize your portfolio returns. This also includes a 14 day full money-back guarantee if you cancel. There is absolutely no risk!  Click Here Now to Get Started! 

Source link

Leave a Reply

Copyright © 2022 Billionaire Club Co LLC. All rights reserved

Loading the chat ...